GSK1004723
| GSK1004723_structure.png | |
GSK1004723 is a chemical compound that has been investigated for its potential therapeutic effects in various medical conditions. It is primarily known for its role as a selective serotonin receptor modulator, which makes it a compound of interest in the treatment of psychiatric disorders such as depression and anxiety.
Mechanism of Action[edit | edit source]
GSK1004723 functions by selectively modulating the activity of serotonin receptors in the brain. Serotonin is a neurotransmitter that plays a crucial role in mood regulation, and its dysregulation is often associated with mood disorders. By targeting specific serotonin receptors, GSK1004723 aims to restore balance in serotonin signaling, potentially alleviating symptoms of depression and anxiety.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of GSK1004723 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. After oral administration, GSK1004723 is absorbed into the bloodstream and distributed throughout the body. It undergoes hepatic metabolism, primarily through the cytochrome P450 enzyme system, and is eventually excreted via the kidneys.
Clinical Trials[edit | edit source]
GSK1004723 has been the subject of several clinical trials aimed at evaluating its efficacy and safety in treating mood disorders. These trials have explored various dosages and administration schedules to determine the optimal therapeutic regimen. Preliminary results have shown promise, but further studies are needed to confirm its clinical benefits and safety profile.
Potential Side Effects[edit | edit source]
As with many pharmacological agents, GSK1004723 may cause side effects. Commonly reported side effects include nausea, headache, dizziness, and insomnia. It is important for patients to be monitored for any adverse reactions during treatment.
Research and Development[edit | edit source]
GSK1004723 is part of ongoing research efforts to develop new treatments for psychiatric disorders. Its development is spearheaded by GlaxoSmithKline, a major pharmaceutical company known for its contributions to neuroscience research. The compound is still under investigation, and its future in clinical use will depend on the outcomes of ongoing and future studies.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
